课题基金 / 基金详情

APPROACHES FOR EFFICIENT INHABITION OF INFLAMMATORY GENES BY SMALL DOSES OF CORTICOSTEROIDS

APPROACHES FOR EFFICIENT INHABITION OF INFLAMMATORY GENES BY SMALL DOSES OF CORTICOSTEROIDS
小剂量皮质类固醇有效抑制炎症基因的方法
批准号:
16590905
负责人:
KASAYAMA Soji
金额:
$2.18万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2004
资助国家:
日本
项目状态:
已结题
起止时间:
2004 至 2005

项目摘要

项目成果

KASAYAMA Soji的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Glucocorticoids are one of the strongest anti-inflammatory drugs. Long-term use of relatively large doses of glucocorticoids is restricted because of various kinds of adverse effects. This investigation was aimed to develop the way how smaller doses of glucocorticoids efficiently exert strong anti-inflammatory effects. Glucocortiocids clearly inhibited TNF-α-induced IL-6 gene promoter activity in cultured bovine aortic endothelial cells (BAECs), whereas they failed to TNF-α-induced VCAM-1 gene promoter activity in BAECs. However, when glucocorticoid receptor (GR) expression vector was introduced into these cells, glucocorticoids could significantly inhibit TNF-α-induced VCAM-1 gene promoter activity. Interestingly, lower concentrations of glucocorticoids were efficient for the inhibition in high GR expressed cells, compared with low GR expressed cells. These results suggest a potential for strong anti-inflammatory effects of low concentrations of glucocorticoids, by increasing GR expression levels in target cells.Activation of PPARα resulted in inhibition of NF-κB binding to specific sequence of the VCAM-1 gene promoter, indicating the inhibitory effect of PPARα on VCAM-1 gene transcription through inhibition of NF-κB activity. MCC-555,an agonist for PPAR three subtypes, was found to inhibit VCAM-1 expression in vascular endothelial cells and monocytes adhesion to these cells. The PPARδ specific agonist GW501516 could also inhibited VCAM-1 expression, while the PPARγ specific agonist pioglitazone did not. Thus, PPARα and δ, but not γ, have the potential to inhibit the VCAM-1 expression in vascular endothelial cells.Activation of PPARα was also found to increase eNOS protein and its mRNA levels in vascular endothelial cells. PPARα activation failed to increase eNOS gene promoter activity, while it stabilized eNOS mRNA. This observation is interesting for understanding the nuclear receptors-mediated stabilization of mRNA.
期刊论文(119)
专著(0)
科研奖励(0)
会议论文
Effects of atendronate on bone mineral density and bone metabolic markers in postmenopausal asthmatic women treated with inhaled corticesteroids.
阿替膦酸钠对接受吸入皮质类固醇治疗的绝经后哮喘女性骨矿物质密度和骨代谢标志物的影响。
DOI: --
发表时间: 2005
期刊: Metabolism 54
影响因子: --
作者: [Kasayama S, Fujita M, Goya K, Yamamoto H, Fujita K, Morimoto Y, Kawase I, Miyatake A]
通讯作者: Miyatake A
Peroxisome proliferators-activated receptor α agonists increase nitric oxide synthase expression in vascular endothelial cells.
过氧化物酶体增殖物激活受体α激动剂增加血管内皮细胞中一氧化氮合酶的表达。
DOI: --
发表时间: 2004
期刊: Arterioscler.Thromb.Vasc Biol. 24
影响因子: --
作者: [Goya K, Sumitani, S, Xu, X, Kitamura, T, Yamamoto, H, Kurebayashi, S, Saito, H, Kouhara, H, Kasayama, S, Kawase, I]
通讯作者: I
ステロイド骨粗鬆症のマネジメント:呼吸器疾患におけるステロイド骨粗鬆症の現状と治療の実際(分担)
类固醇性骨质疏松症的管理:类固醇性骨质疏松症在呼吸系统疾病中的现状和实际治疗(分享)
DOI: --
发表时间: 2005
期刊:
影响因子: --
作者: [笠山宗正, ほか]
通讯作者: ほか
わが国における骨粗鬆症診療の実態
日本骨质疏松症治疗现状
DOI: --
发表时间: 2005
期刊: 綜合臨床 54
影响因子: --
作者: [紅林昌吾, ほか]
通讯作者: ほか
38
    Regulatory mechanisms of cytokines and adhesion molecules gene expression by nuclear receptors: for the development of new anti-inflammatory drugs
    • 批准号:
      13671153
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.24万
    • 财政年份:
      2001
    • 负责人:
      KASAYAMA Soji
    • 依托单位:
    Biological Roles of PPAR-γ and C/EBP on Adipogenesis and SCD-1 Gene Expression
    • 批准号:
      10671066
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.3万
    • 财政年份:
      1998
    • 负责人:
      KASAYAMA Soji
    • 依托单位:
    国内基金
    海外基金
    早期滋养型肠内营养联合益生菌对重症卒中患者喂养耐受性及TNF-α/IL-6水平的影响研究
    七氟烷通过调控IL-6/FSP1轴抑制心肌铁死亡减轻心肌缺血再灌注损伤的机制研究
    • 批准号:
      JCZRLH202601296
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2026
    • 负责人:
    • 依托单位:
    盐酸小檗碱抑制NF-κB/IL-6/STAT3信号通路重塑免疫微环境并增敏肺癌免疫治疗的研究
    • 批准号:
      JCZRLH202600985
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2026
    • 负责人:
    • 依托单位:
    双歧杆菌与消退素RvD1协同调控IL-6/STAT3/Notch信号轴介导结肠癌EMT及免疫调节的机制研究
    • 批准号:
      JCZRLH202601410
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2026
    • 负责人:
    • 依托单位: